Literature DB >> 15101771

Construction of a C(30-38) dioxabicyclo[3.2.1]octane subtarget for (+)-sorangicin A, exploiting a regio- and stereocontrolled acid-catalyzed epoxide ring opening.

Amos B Smith1, Richard J Fox.   

Abstract

[reaction: see text] In this paper, we report assembly of the novel dioxabicyclo[3.2.1]octane subtarget (-)-2, comprising the signature structural element of the potent antibiotic (+)-sorangicin A (1). The synthesis was achieved in 15 steps (1.5% overall yield) via a series of acid-catalyzed epoxide ring openings. The first, facilitated by the complex of alkyne (+)-3 with Co(2)(CO)(8), proceeded in a highly regio- and stereoselective fashion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15101771     DOI: 10.1021/ol049644s

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  5 in total

1.  Formal synthesis of (+)-sorangicin A.

Authors:  Michael T Crimmins; Matthew W Haley; Elizabeth A O'Bryan
Journal:  Org Lett       Date:  2011-08-11       Impact factor: 6.005

2.  (+)-Sorangicin A: evolution of a viable synthetic strategy.

Authors:  Amos B Smith; Shuzhi Dong; Richard J Fox; Jehrod B Brenneman; John A Vanecko; Tomohiro Maegawa
Journal:  Tetrahedron       Date:  2011-12-23       Impact factor: 2.457

3.  Total synthesis of (+)-sorangicin A.

Authors:  Amos B Smith; Shuzhi Dong; Jehrod B Brenneman; Richard J Fox
Journal:  J Am Chem Soc       Date:  2009-09-02       Impact factor: 15.419

4.  An efficient, second-generation synthesis of the signature dioxabicyclo[3.2.1]octane core of (+)-sorangicin A and elaboration of the (Z,Z,E)-triene acid system.

Authors:  Amos B Smith; Shuzhi Dong
Journal:  Org Lett       Date:  2009-03-05       Impact factor: 6.005

5.  Function-Oriented Studies Targeting Pectenotoxin 2: Synthesis of the GH-Ring System and a Structurally Simplified Macrolactone.

Authors:  Natasha F O'Rourke; Mu A; Henry N Higgs; Alan Eastman; Glenn C Micalizio
Journal:  Org Lett       Date:  2017-09-13       Impact factor: 6.005

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.